Facebook
X
LinkedIn
ForwardNCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium
The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.
Target Audience
This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician associates, pharmacists, case managers, oncology data specialists, social workers, and other health care professionals who treat patients with breast cancer.
Learning Objectives
The goal of the program is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:
- Summarize the current recommendations for oncology care, key updates in the NCCN Guidelines®, and clinical research updates from the 2025 SABCS and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer.
- Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with cancer and the delivery of oncology care.
Click here to view the learning objectives for each session.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Presenting Faculty
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Bethany M. Anderson, MD
Ann Marie Flores, PT, MSPT, MA, PhD
Tuya Pal, MD
Laura H. Rosenberger, MD, MS
Wafa Samara, PharmD
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Meghan R. Flanagan, MD, MPH
Intuitive Surgical, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Perimeter Medical Imaging AI: Grant/Research Support
Lisa E. Flaum, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Biotheranostics: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
William J. Gradishar, MD (Congress Chair and Moderator)
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor
Frederick M. Howard, MD
Leica Biosystems: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Irene Kang, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
BioNTech: Consulting Fee
Caris Life Sciences: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc. Consulting Fee
Menarini Stemline: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Melissa M. McShane, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Melinda L. Telli, MD
Arvinas: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BioNTech: Grant/Research Support; Scientific Advisor
Blueprint Medicines: Scientific Advisor
Celcuity: Consulting Fee
Foresight Diagnostics: Scientific Advisor
G1 Therapeutics: Consulting Fee
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Lilly: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Natera: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
OncoSec Medical: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Summit Therapeutics: Scientific Advisor
Kay T. Yeung, MD, PhD
Alterome Therapeutics: Grant/Research Support
Arvinas: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BioFluidica: Grant/Research Support
BriaCell Therapeutics: Grant/Research Support
Dantari, Inc.: Grant/Research Support
Endeavor BioMedicines: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Greenwich Therapeutics: Grant/Research Support
Iambic Therapeutics: Grant/Research Support
Immunomedics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
MOMA Therapeutics: Grant/Research Support
OBI Pharma: Grant/Research Support
OnKure Therapeutics: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Poseidon Therapeutics: Grant/Research Support
Pyxis Oncology: Grant/Research Support
Regeneron Pharmactcls: Grant/Research Support
Regor Therapeutics: Grant/Research Support
Relay Therapeutics: Grant/Research Support
SeaGen: Grant/Research Support
Stemline Therapeutics: Grant/Research Support
Zymeworks: Grant/Research Support
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Joint Accreditation
 | In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. |
Physicians
NCCN designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 6.5 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 6.5 contact hours (0.65 CEUs) of continuing education credit. UAN: JA4008196-0000-26-016-L01-P
Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Social Workers
As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 6.5 continuing education credits.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 6.5 CE contact hours.
Activity Code: C00066011 | Approval Number: 260000065
American Board of Internal Medicine Maintenance of Certification (MOC)
 | Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity. |
American Board of Pathology Continuing Certification (CC)
 | This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 6.5 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity. |
American Board of Surgery Continuous Certification (CC)
 | Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. |
American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:
Oncology Data Specialists (Virtual Attendance)
 | The “NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium” program supports 6.5 CE hours of which 4.25 hours meet the Category A requirement. This program has been assigned the following event number: 2025-363. |
Oncology Data Specialists (In-Person Attendance)
 | The “NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium” program supports 6.5 CEIP hours of which 4.25 hours meet the Category A requirement. This program has been assigned the following event number: 2025-363IP. |
Permission to Upload Credits
For ABIM, ABPath, and ABS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.
By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.
Available Credit
- 6.50 AAPA Category 1 CME credit
- 6.50 ACPE contact hours
- 6.50 AMA PRA Category 1 Credit™
- 6.50 ANCC contact hours
- 6.50 ASWB continuing education credit
- 6.50 CCM clock hours
- 6.50 Participation
- 6.50 NCRA CEIP Hours
- 4.25 Category A (IP)
- 6.50 NCRA CE hours
- 4.25 Category A
Please log in with the email address you used for event registration.
Click the Take Course button to proceed with credit claiming.
CE/MOC credit should be claimed for the congress as a whole, not session by session. You may claim credit for the congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording.
Pharmacists: you must complete all requirements for credit by March 23, 2026.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing